In humans and mice, many B-cells of fetal or neonatal origin produce autoantibodies. Typically these cells are CD5+ and their antibodies are IgM and lack somatic mutations. Several lines of evidence implicate CD5+ B-cells in some forms of autoimmunity, both human and murine. Further, there is strong evidence indicating that some pathogenic, somatically mutated, IgG autoantibodies are derived from the fetal/neonatal repertoire. The problem arises as to the events in autoimmune prone individuals that induce somatic mutation and isotype switching in autoantibody producing B-cells. While both environmental and genetic events might be responsible, the investigators are interested in those events intrinsic to B-cells. Their proposal is designed to test the hypothesis that there are normal restraints intrinsic to the producers of natural autoantibody (CD5+ B-cells) that prevent them from progressing via somatic mutation and isotype switching to the production of pathogenic autoantibody. Possible internal restraints on CD5 B-cells include: an inability to participate in cognate interactions with T helper cells; a failure to express the machinery needed for somatic mutation, sensitivity to tolerance induction. The experiments proposed are based on their recent work showing that the B-cell CD5+ CD23low (B-1a) phenotype can be induced by thymus independent type 2 (slg cross-linking) activation, while cognate interactions leading to activation via CD40-ligand on activated T helper cells generates CD5-CD23hi B-cells. These findings indicate that naive B-cells can respond to alternative activation signals by expressing different surface phenotypes. The investigators will test the proposition that natural autoantibody producing (B-1) cells from normal mouse strains are poor responders (compared to B-2 cells) to slg cross-linking, CD40 ligation or cognate interactions with helper T-cells. They will also compare the ability of B-1 and B-2 cells to generate somatic mutations in response to in vivo or in vitro stimulation with cognate T helper cells. They further suggest, and will test, the proposition that the B-1 cells of autoimmune prone strains, in contrast to B-1 cells of wild type origin, can participate in cognate interactions with T helper cells, resulting in mutation and clonal expansion of cells producing high-affinity autoantibodies, and, ultimately, significant pathology. If validated, this would help to explain the many hitherto puzzling observations which link polysystem autoimmune disease with natural autoantibodies and CD5+ B-cells.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
5R01AR043773-02
Application #
2517503
Study Section
Immunological Sciences Study Section (IMS)
Project Start
1996-09-30
Project End
2001-08-31
Budget Start
1997-09-01
Budget End
1998-08-31
Support Year
2
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Tufts University
Department
Pathology
Type
Schools of Medicine
DUNS #
604483045
City
Boston
State
MA
Country
United States
Zip Code
02111
Berland, Robert; Fiering, Steven; Wortis, Henry H (2010) A conserved enhancer element differentially regulates developmental expression of CD5 in B and T cells. J Immunol 185:7537-43
Jin, Lei; McLean, Paul A; Neel, Benjamin G et al. (2002) Sialic acid binding domains of CD22 are required for negative regulation of B cell receptor signaling. J Exp Med 195:1199-205
Ma, Limei; Wortis, Henry H; Kenter, Amy L (2002) Two new isotype-specific switching activities detected for Ig class switching. J Immunol 168:2835-46
Lin, S C; Wortis, H H; Stavnezer, J (1998) The ability of CD40L, but not lipopolysaccharide, to initiate immunoglobulin switching to immunoglobulin G1 is explained by differential induction of NF-kappaB/Rel proteins. Mol Cell Biol 18:5523-32
Nadler, M J; McLean, P A; Neel, B G et al. (1997) B cell antigen receptor-evoked calcium influx is enhanced in CD22-deficient B cell lines. J Immunol 159:4233-43
Nadler, M J; Chen, B; Anderson, J S et al. (1997) Protein-tyrosine phosphatase SHP-1 is dispensable for FcgammaRIIB-mediated inhibition of B cell antigen receptor activation. J Biol Chem 272:20038-43